Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?

Marwan N. Sabbagh, Martin R. Farlow, Normal Relkin, Thomas G. Beach

Research output: Contribution to journalReview article

42 Citations (Scopus)

Abstract

The most widely studied and used therapies for Alzheimer's disease (AD) are based on improving cholinergic function in the central nervous system. The acetylcholine-esterase inhibitors (ChEIs) tacrine, donepezil, rivastigmine, and galantamine are all approved, and the latter three are widely used for the symptomatic treatment of mild to moderate AD. Recent research has found that these drugs may act by a variety of other mechanisms including inhibition of butylcholinesterase, regulation of nicotinic receptors, decreasing amyloid precursor protein (APP) and Aβ production, and regulation of tau phosphorylation that may influence disease progression. There is also emerging evidence from clinical trials that the ChEIs may delay cognitive and functional progression. Other cholinergic drugs such as muscarinic agonists have been explored, and although they are not approved, there is robust preclinical evidence for a beneficial, perhaps disease-modifying effect. This review summarizes evidence suggesting that these drugs may do more than improve symptoms; they may delay biological progression of the disease.

Original languageEnglish (US)
Pages (from-to)118-125
Number of pages8
JournalAlzheimer's and Dementia
Volume2
Issue number2
DOIs
StatePublished - Apr 1 2006

Fingerprint

Serum Amyloid A Protein
Rivastigmine
Cholinergic Agents
Disease Progression
Alzheimer Disease
Galantamine
Tacrine
Muscarinic Agonists
Amyloid beta-Protein Precursor
Nicotinic Receptors
Esterases
Pharmaceutical Preparations
Acetylcholine
Central Nervous System
Phosphorylation
Clinical Trials
Therapeutics
Research
Inhibition (Psychology)
donepezil

Keywords

  • Alzheimer's disease
  • Cholinesterase inhibitors
  • Muscarinic
  • Prevention
  • Therapy

ASJC Scopus subject areas

  • Health Policy
  • Epidemiology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health
  • Cellular and Molecular Neuroscience
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

Do cholinergic therapies have disease-modifying effects in Alzheimer's disease? / Sabbagh, Marwan N.; Farlow, Martin; Relkin, Normal; Beach, Thomas G.

In: Alzheimer's and Dementia, Vol. 2, No. 2, 04.2006, p. 118-125.

Research output: Contribution to journalArticle

Sabbagh, Marwan N. ; Farlow, Martin R. ; Relkin, Normal ; Beach, Thomas G. / Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?. In: Alzheimer's and Dementia. 2006 ; Vol. 2, No. 2. pp. 118-125.
@article{e98dfb66d27a4dc880264c19e8ff6b97,
title = "Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?",
abstract = "The most widely studied and used therapies for Alzheimer's disease (AD) are based on improving cholinergic function in the central nervous system. The acetylcholine-esterase inhibitors (ChEIs) tacrine, donepezil, rivastigmine, and galantamine are all approved, and the latter three are widely used for the symptomatic treatment of mild to moderate AD. Recent research has found that these drugs may act by a variety of other mechanisms including inhibition of butylcholinesterase, regulation of nicotinic receptors, decreasing amyloid precursor protein (APP) and Aβ production, and regulation of tau phosphorylation that may influence disease progression. There is also emerging evidence from clinical trials that the ChEIs may delay cognitive and functional progression. Other cholinergic drugs such as muscarinic agonists have been explored, and although they are not approved, there is robust preclinical evidence for a beneficial, perhaps disease-modifying effect. This review summarizes evidence suggesting that these drugs may do more than improve symptoms; they may delay biological progression of the disease.",
keywords = "Alzheimer's disease, Cholinesterase inhibitors, Muscarinic, Prevention, Therapy",
author = "Sabbagh, {Marwan N.} and Farlow, {Martin R.} and Normal Relkin and Beach, {Thomas G.}",
year = "2006",
month = "4",
day = "1",
doi = "10.1016/j.jalz.2006.02.001",
language = "English (US)",
volume = "2",
pages = "118--125",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Do cholinergic therapies have disease-modifying effects in Alzheimer's disease?

AU - Sabbagh, Marwan N.

AU - Farlow, Martin R.

AU - Relkin, Normal

AU - Beach, Thomas G.

PY - 2006/4/1

Y1 - 2006/4/1

N2 - The most widely studied and used therapies for Alzheimer's disease (AD) are based on improving cholinergic function in the central nervous system. The acetylcholine-esterase inhibitors (ChEIs) tacrine, donepezil, rivastigmine, and galantamine are all approved, and the latter three are widely used for the symptomatic treatment of mild to moderate AD. Recent research has found that these drugs may act by a variety of other mechanisms including inhibition of butylcholinesterase, regulation of nicotinic receptors, decreasing amyloid precursor protein (APP) and Aβ production, and regulation of tau phosphorylation that may influence disease progression. There is also emerging evidence from clinical trials that the ChEIs may delay cognitive and functional progression. Other cholinergic drugs such as muscarinic agonists have been explored, and although they are not approved, there is robust preclinical evidence for a beneficial, perhaps disease-modifying effect. This review summarizes evidence suggesting that these drugs may do more than improve symptoms; they may delay biological progression of the disease.

AB - The most widely studied and used therapies for Alzheimer's disease (AD) are based on improving cholinergic function in the central nervous system. The acetylcholine-esterase inhibitors (ChEIs) tacrine, donepezil, rivastigmine, and galantamine are all approved, and the latter three are widely used for the symptomatic treatment of mild to moderate AD. Recent research has found that these drugs may act by a variety of other mechanisms including inhibition of butylcholinesterase, regulation of nicotinic receptors, decreasing amyloid precursor protein (APP) and Aβ production, and regulation of tau phosphorylation that may influence disease progression. There is also emerging evidence from clinical trials that the ChEIs may delay cognitive and functional progression. Other cholinergic drugs such as muscarinic agonists have been explored, and although they are not approved, there is robust preclinical evidence for a beneficial, perhaps disease-modifying effect. This review summarizes evidence suggesting that these drugs may do more than improve symptoms; they may delay biological progression of the disease.

KW - Alzheimer's disease

KW - Cholinesterase inhibitors

KW - Muscarinic

KW - Prevention

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=33645756861&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645756861&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2006.02.001

DO - 10.1016/j.jalz.2006.02.001

M3 - Review article

C2 - 19595868

AN - SCOPUS:33645756861

VL - 2

SP - 118

EP - 125

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 2

ER -